TriSalus Life Sciences Reports Third Quarter 2026 Results
Business Wire•10/11/2026•08:05 ET
0
Key Highlights
- ➤Q3 revenue $12.9 million, up 11.3% year over year
- ➤2026 revenue guidance revised to $46 million-$48 million
- ➤CMS raised C8004 Medicare payment to approximately $20,910 effective 2027
- ➤CMS established approximately $13,800 office-based lab payment for PEDD procedures
- ➤TriNav Advance received FDA clearance for small distal-vessel procedures
Expert Statements
Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences
“The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice. This clearance allows us to address the full range of vessels encountered in liver embolization procedures going forward.”
Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences
“Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists. Combined with the launch of TriNav Advance, expanded access to office-based labs through the new G-code, and continued cost discipline, we believe we have laid the foundation for continued growth in 2027 and beyond.”
Generated third quarter revenue of $12.9 million, driven by expanded commercial organization and increasing market penetration
Centers for Medicare & Medicaid Services finalized policies that expand favorable reimbursement for procedures using PEDD for 2027
Get started
Create a free account to read the full story.